Jemperli Wins FDA Approval as First Immunotherapy for MSI-H/dMMR Rectal Cancer
GSK sits 16% above its 52-week low of $42.845.
Summary
GSK's Jemperli became the first immunotherapy approved in the US for MSI-H/dMMR locally advanced rectal cancer, with AZUR-1 data showing 68% of evaluable patients in sustained clinical complete response at 12 months and no relapses among responders after two-plus years.
Key Events · Product Development and Regulatory · GSK
-
FDA Approves Jemperli in Rectal Cancer
Accelerated approval for adults with stage II/III MSI-H/dMMR locally advanced rectal cancer — the first and only immunotherapy cleared for this indication.
-
AZUR-1 Response Rates Disclosed
68% (98/144) achieved cCR12 on investigator assessment; 47% (54/116) by independent central review, which continues to mature. 76% (110/144) had no evidence of cancer at one year or more.
-
No Recurrences in Responders
No disease recurrences reported among responders after median follow-up of more than two years.
-
Approval Arrives Ahead of PDUFA
Priority Review plus a National Priority Voucher produced approval ahead of the February PDUFA date; reviews continue in other countries under Project Orbis.
Analysis · GSK · Life Sciences
Jemperli is now the first and only approved immunotherapy for stage II/III MSI-H/dMMR locally advanced rectal cancer, arriving ahead of the February PDUFA date via a National Priority Voucher. The AZUR-1 data are the story: 68% of evaluable patients (98/144) had a sustained clinical complete response at 12 months on investigator assessment, and no responders have relapsed after more than two years of median follow-up. That opens a chemotherapy-, radiation- and surgery-free path for a biomarker-defined population, though the eligible pool is narrow — MSI-H/dMMR accounts for only about 5-10% of rectal cancers — and the accelerated approval rests on a single-arm trial whose independent central review endpoint (47%, 54/116) is still maturing. For a company this size the near-term revenue is modest; the value is in extending Jemperli's label into gastrointestinal cancers and reinforcing GSK's oncology build-out.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 37.9% of the 895 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.87%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GSK was trading at $49.52 on NYSE in the Life Sciences sector, with a market capitalization of approximately $99.5B. The 52-week trading range was $42.85 to $61.70. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.